ANDA
E642121
ANDA stands for Abbreviated New Drug Application, the U.S. FDA regulatory pathway that allows approval of generic drugs by demonstrating bioequivalence to an already approved brand-name product.
All labels observed (1)
| Label | Occurrences |
|---|---|
| ANDA canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T7110944 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ANDA Context triple: [Drug Price Competition and Patent Term Restoration Act of 1984, abbreviation, ANDA]
-
A.
ANDICAM
ANDICAM is a dual-channel optical and near-infrared imager and spectrograph used in astronomical observations on the SMARTS 1.3-meter Telescope.
-
B.
Anput
Anput is an ancient Egyptian goddess associated with funerary rites and protection, often depicted as a female counterpart to the jackal-headed god Anubis.
-
C.
ANLE
ANLE is the North American Academy of the Spanish Language, an institution dedicated to studying, preserving, and promoting the correct use of Spanish in the United States.
-
D.
ANA
ANA is the commonly used abbreviation for the Afghan National Army, the former main land warfare branch of Afghanistan’s armed forces.
-
E.
ANA
ANA is the standard three-letter abbreviation used for the Anaheim Ducks, a professional ice hockey team in the National Hockey League.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: ANDA Target entity description: ANDA stands for Abbreviated New Drug Application, the U.S. FDA regulatory pathway that allows approval of generic drugs by demonstrating bioequivalence to an already approved brand-name product.
-
A.
ANDICAM
ANDICAM is a dual-channel optical and near-infrared imager and spectrograph used in astronomical observations on the SMARTS 1.3-meter Telescope.
-
B.
Anput
Anput is an ancient Egyptian goddess associated with funerary rites and protection, often depicted as a female counterpart to the jackal-headed god Anubis.
-
C.
ANLE
ANLE is the North American Academy of the Spanish Language, an institution dedicated to studying, preserving, and promoting the correct use of Spanish in the United States.
-
D.
ANA
ANA is the standard three-letter abbreviation used for the Anaheim Ducks, a professional ice hockey team in the National Hockey League.
-
E.
ANA
ANA is the commonly used abbreviation for the Afghan National Army, the former main land warfare branch of Afghanistan’s armed forces.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
Abbreviated New Drug Application
ⓘ
U.S. drug approval application type ⓘ regulatory pathway ⓘ |
| abbreviationFor |
Abbreviated New Drug Application
ⓘ
linked to:
Abbreviated New Drug Application process
|
| applicationType | abbreviated application ⓘ |
| appliesTo | generic drugs ⓘ |
| associatedWith | Orange Book ⓘ |
| comparedTo | New Drug Application ⓘ |
| differsFrom | New Drug Application ⓘ |
| doesNotRequire |
independent clinical efficacy trials in most cases
ⓘ
independent clinical safety trials in most cases ⓘ |
| fullForm |
Abbreviated New Drug Application
ⓘ
linked to:
Abbreviated New Drug Application process
|
| goal |
ensure therapeutic equivalence to reference listed drugs
ⓘ
provide lower-cost alternatives to brand-name drugs ⓘ |
| includes |
bioequivalence study reports
ⓘ
drug product information ⓘ drug substance information ⓘ manufacturing site information ⓘ proposed labeling ⓘ stability data ⓘ |
| jurisdiction |
United States
ⓘ
linked to:
United States of America
|
| language | English ⓘ |
| legalBasis |
Federal Food, Drug, and Cosmetic Act
ⓘ
Hatch-Waxman Amendments ⓘ |
| mayInclude | biowaiver requests for certain dosage forms ⓘ |
| NDAComparison | relies on existing safety and efficacy data of reference drug ⓘ |
| outcome | approval to market a generic drug in the U.S. ⓘ |
| purpose | approval of generic drug products ⓘ |
| referenceProductType |
brand-name drug
ⓘ
reference listed drug ⓘ |
| regulatedBy |
FDA
ⓘ
linked to:
Food and Drug Administration
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| relatedTo |
drug patent and exclusivity framework
ⓘ
generic drug competition ⓘ |
| requires |
chemistry, manufacturing, and controls information
ⓘ
demonstration that inactive ingredients are safe ⓘ drug product quality data ⓘ labeling information ⓘ patent certification ⓘ pharmacokinetic bioequivalence studies in many cases ⓘ |
| requiresDemonstrationOf | bioequivalence ⓘ |
| reviewedBy |
FDA Office of Generic Drugs
ⓘ
linked to:
Office of Generic Drugs
OGD ⓘ |
| submissionFormat |
eCTD
ⓘ
electronic Common Technical Document ⓘ |
| submissionTo |
CDER
ⓘ
linked to:
Center for Drug Evaluation and Research
Center for Drug Evaluation and Research ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: ANDA Description of subject: ANDA stands for Abbreviated New Drug Application, the U.S. FDA regulatory pathway that allows approval of generic drugs by demonstrating bioequivalence to an already approved brand-name product.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.